Tag Archive for revenue 2024

USANA Q2 Revenue 11% Down To $213 Million

USANA Health Sciences, Inc.announced financial results for its fiscal second quarter ended June 29, 2024.
Key Financial & Operating Results

Second quarter net sales were $213 million versus $238 million during Q2 2023.
Second quarter diluted EPS was $0.54 as compared with $0.89 during Q2 2023.
Company updates fiscal year 2024 net sales and diluted EPS outlook to $850 million to $880 million and $2.40 to $2.55 (previously $850 million to $920 million and $2.40 to $3.00).

“Second quarter operating results were below our expectations,”

said Jim Brown, President and Chief Executive Officer.

“Ongoing macroeconomic pressures in several of our key markets continue to impact consumer spending. This in turn creates challenges in our ability to attract and engage new customers and generate sales momentum.
To counter these challenges, we have made several strategic changes in our business over the past few quarters, including (i) restructuring our commercial team, (ii) heightening our focus on product innovation, (iii) increasing our efforts to engage our sales leaders with an Associate-first approach, (iv) expanding into India, and (v) evaluating more business development activities.
“Next month, we will be hosting our Americas & Europe Convention in Las Vegas, Nevada along with other Associate engagement-focused events in the back half of the

Read more...

Zinzino First Half Year Sales Up 20% To Euro 801,6 Million

Revenues in the second quarter of 2024 amounted to SEK 507.0 (407.9) million, corresponding to 24% (24%) growth compared to the corresponding period last year. EBITDA increased to SEK 63.0 (53.7) million, and the EBITDA margin amounted to 12.4% (13.2%).
During the quarter, Zinzino acquired the rights to Luxembourg-based Xelliss SA distributor database, inventory and IP assets, acquired 49% of the shares in the Cypriot olive oil producer Cleanthi Alpha-Olenic LTD and signed a letter of intent to acquire the US direct sales company Zurvita INC. In addition, the launch of Serbia was announced as the next step in the global expansion.
APRIL-JUNE
• Total revenue amounted to SEK 507.0 (407.9) million, corresponding to a growth of 24% (24%)
• Gross profit amounted to SEK 174.5 (148.5) million and the gross profit margin amounted to 34.4% (36.4%)
• EBITDA profit amounted to SEK 63.0 (53.7) million and the EBITDA margin amounted to 12.4% (13.2%)
• Cash flow from operating activities amounted to SEK 91.1 (46.3) million
JANUARY-JUNE
• Total revenue amounted to SEK 961.6 (801.6) million, corresponding to a growth of 20% (21%)
• Gross profit amounted to SEK 335.4 (279.2) million, and the gross profit margin amounted to 34.9% (34.8%)
• EBITDA profit amounted to SEK 114.7 (98.1) million,

Read more...

USA Q2 Revenue 2024 Down 11% To $ 213 Million

USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal second quarter ended June 29, 2024.
Key Financial & Operating Results

Second quarter net sales were $213 million versus $238 million during Q2 2023.
Second quarter diluted EPS was $0.54 as compared with $0.89 during Q2 2023.
Company updates fiscal year 2024 net sales and diluted EPS outlook to $850 million to $880 million and $2.40 to $2.55 (previously $850 million to $920 million and $2.40 to $3.00).

“Second quarter operating results were below our expectations,”

said Jim Brown, President and Chief Executive Officer.

“Ongoing macroeconomic pressures in several of our key markets continue to impact consumer spending. This in turn creates challenges in our ability to attract and engage new customers and generate sales momentum.
To counter these challenges, we have made several strategic changes in our business over the past few quarters, including (i) restructuring our commercial team, (ii) heightening our focus on product innovation, (iii) increasing our efforts to engage our sales leaders with an Associate-first approach, (iv) expanding into India, and (v) evaluating more business development activities.
“Next month, we will be hosting our Americas & Europe Convention in Las Vegas, Nevada along with other Associate engagement-focused events in the back half of the year. We are also planning to offer a more robust promotional calendar throughout the remainder of the year.”

Balance Sheet and Share Repurchase Activity
The Company generated $8 million in operating

Read more...

Zinzino January 2024 Revenue Up 15% To $14 Million

According to a Zinzino press release:
Zinzino group revenue increased with a total of 15%, compared with the previous year.
The revenue in January for Zinzino’s sales markets increased by 17% and amounted to SEK 140.2 (120.3) million.
Faun Pharma’s external sales decreased by 11% and amounted to SEK 8.1 (9.1) million.

Overall, the Group increased revenues by 15% to SEK 148.3 (129.4) million compared with the previous year.

About Zinzino
Zinzino AB (publ.) is a global Direct Sales company that markets and sells test-based nutrition, skincare and life-style products. Zinzino owns the research unit BioActive Foods AS and production unit Faun Pharma AS.
Zinzino is based in Gothenburg, with additional offices in Finland, Latvia, Norway, USA, Australia, Hong Kong and Malaysia. Zinzino is a public company and its shares are listed on Nasdaq First North Premier Growth Market. For more informaton please visit www.zinzino.com
 
The post Zinzino January 2024 Revenue Up 15% To $14 Million appeared first on Direct Selling Facts, Figures and News.

Read more...